Lazertinib Mesylate

甲磺酸兰泽替尼

Report date: 2026/04/29 20:02:18
NME

Base Information

Drug NameLazertinib Mesylate
Drug Alias Name拉泽替尼lasertinib兰泽替尼LazertinibLeclaza +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR T790M inhibitorsEGFR L858R inhibitorsEGFR 19del inhibitors +[4] 
TargetsEGFR T790MEGFR L858REGFR 19del +[4] 
Therapy Area/IndicationsHepatic InsufficiencyCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritorySouth Korea
Original Approved Date2021/01/18
Country/TerritoryBelgiumCanadaUnited States +[33] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesOscotec IncJanssen Biotech IncYuhan Corp
China Registration ClassN/A

Develop Information

Active CompaniesJanssen-Cilag International NvJanssen Pharmaceutical KkJanssen Biotech Inc +[6] 
Inactive CompaniesYonsei UniversityKonkuk University Medical Center
Active IndicationsHepatic InsufficiencyCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeL01EB09
Related LinksDrugBankKEGG